<DOC>
	<DOCNO>NCT01885897</DOCNO>
	<brief_summary>This multi-center , phase I/II clinical trial patient relapse 60 day allogeneic transplant hematologic malignancy . The study consist two phase . The dose finding phase modify version phase I trial extend phase modify version phase II trial . The primary objective dose find phase determine maximum tolerate , minimum efficacious dose ( MTD/MED ) interleukin-15 ( IL-15 ) super agonist complex ( ALT-803 ) give weekly 4 week outpatient set . The study follow standard 3+3 design dose escalation toxicity add feature stop early efficacy confirm . There six dose level ALT-803 determine MTD/MED : 1 , 3 , 6 , 10 , 20 , 30 mcg/kg . Once MTD/MED ALT-803 determine , cohort use extended phase . The primary goal extend phase study potential efficacy ALT-803 patient population . Efficacy measure use rate remission induction . An optimal Simon 's two-stage design use phase . Stage 1 enroll 14 patient ( include 6 patient treat MTD/MED dose find phase ) . If 3 14 patient respond ALT-803 , trial move stage 2 enroll additional 23 patient . If 2 few respond , study terminate enrollment early .</brief_summary>
	<brief_title>IL-15 Super Agonist ALT-803 Treat Relapse Of Hematologic Malignancy After Allogeneic SCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Relapse previous allogeneic stem cell transplant one follow hematologic malignancy ( acute myelogenous leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome , lymphoma , myeloma , Chronic lymphocytic Leukemia , chronic myelogenous leukemia ) : For nonCML , relapse define base disease specific morphologic criterion bone marrow biopsy aspirate recurrence disease specific cytogenetics . For disease specific definition relapse , see appendix III . Relapse determine morphologically . Equivocal result relapse result repeat test appropriate time interval ( suggested 1 month ) determine eligibility . For CML , relapse define cytogenetic evidence Philadelphia chromosome persistence BCR/ABL rearrangements molecular test least two measurement 6 month interval . If cytogenetics normal PCR evidence BCR/ABL fusion , patient eligible evidence quantitative increase CML measure either quantitative PCR fluorescent situ hybridization ( FISH ) . For Chronic Phase CML patient : must fail ( response 3 month incomplete response 6 month ) refuse treatment tyrosinekinase inhibitor ( TKI ) must fail ( defined incomplete response relapse ) refuse DLI Relapse must occur ≥ 60 day transplant Prior DLI allow , however within 30 day 1st dose ALT803 Minimum donor chimerism 10 % ≥ 18 year age Karnofsky performance status ≥ 70 % ( appendix II ) Adequate organ function within 14 day ( 30 day cardiac pulmonary ) enrollment define : Creatinine : ≤ 2.0 mg/dL Hepatic : SGOT/SGPT &lt; 5 x upper limit institutional normal ( ULN ) Thyroid Function : Thyroid Stimulating Hormone ( TSH ) within institutional normal range patient thyroid disease eligible euthyroid suppressive replacement therapy Pulmonary : PFTs &gt; 50 % predicted Cardiac : LVEF ECHO MUGA &gt; 40 % Ability prednisone immunosuppressive drug least 30 day first dose study drug Patient agree stay within reasonable distance ( i.e . 30 mile ) study site duration study treatment minimum 48 hour last dose dedicate care giver standard practice BMT outpatient care Women child bear potential men partner child bear potential must agree use effective contraception therapy 4 month completion therapy Voluntary write consent Posttransplant lymphoproliferative disease ( often refer EBVassociated lymphoma ) Known active CNS leukemia lymphoma patient previously treat CNS disease permit neurologically stable ongoing anticipated need steroid therapy eligible Ongoing active acute chronic GVHD require immunosuppressive therapy sign aGVHD cGVHD require treatment Pregnant lactate Women child bear potential must negative pregnancy test within 14 day study treatment start Class II great New York Heart Association Functional Classification criterion ( appendix II ) serious cardiac arrhythmia likely increase risk cardiac complication cytokine therapy ( e.g . ventricular tachycardia , frequent ventricular ectopy , supraventricular tachyarrhythmia require chronic therapy Marked baseline prolongation QT/QTc interval ( e.g . demonstration QTc interval great 500 millisecond ) New progressive pulmonary infiltrates screen chest xray chest CT scan evaluation bronchoscopy feasible . Infiltrates attribute infection must stable/improving ( associated clinical improvement ) 1 week appropriate therapy ( 4 week presume documented fungal infection ) . Active bacterial , fungal , viral infection prior infection must resolve follow optimal therapy Positive hepatitis C serology active hepatitis B infection risk hepatic inflammation possible confound drug toxicity assessment chronic asymptomatic viral hepatitis allow HIV positive effect IL15 viral load , HIV immunity , infectivity proliferate T cell unknown History severe asthma , presently chronic medication ( history mild asthma require therapy eligible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute myelogenous leukemia ( AML )</keyword>
	<keyword>Acute lymphoblastic leukemia ( ALL )</keyword>
	<keyword>Myelodysplastic syndrome ( MDS )</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Chronic myelogenous leukemia ( CML )</keyword>
</DOC>